--- title: "Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296708698.md" description: "Biohaven reported Q2 2026 results with a reduced net loss of $137.31 million, improving significantly from the prior year. Despite this earnings improvement and recent stock momentum, the company remains unprofitable with minimal revenue and less than one year of cash runway. Valuation analysis presents conflicting signals: Biohaven trades at an extremely high price-to-book ratio of 171.2x compared to industry averages, yet a DCF model suggests the stock is undervalued by approximately 74.3% relative to future cash flow estimates." datetime: "2026-08-23T19:37:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296708698.md) - [en](https://longbridge.com/en/news/296708698.md) - [zh-HK](https://longbridge.com/zh-HK/news/296708698.md) generator: "portal-rs" --- # Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement? ## Biohaven earnings update and what it means for investors Biohaven (BHVN) reported second quarter 2026 results that showed a reduced net loss of US$137.31 million. Loss per share from continuing operations was US$0.91, compared with US$1.94 a year earlier. For the first half of 2026, Biohaven reported a net loss of US$267.84 million, with basic loss per share from continuing operations of US$1.80, compared with US$4.11 in the prior year period. See our latest analysis for Biohaven. Biohaven’s latest earnings release arrives after a mixed year for investors, with the share price up 46.56% over the past 90 days and 27.77% year to date, but the 1 year total shareholder return down 11.27%. This points to improving short term momentum against a weaker longer term experience. If you are weighing Biohaven’s recent move against other ideas in healthcare, this can be a good moment to see which companies are powering the next wave of medical AI through our 40 healthcare AI stocks Biohaven trades at a steep discount to both analyst targets and some fair value estimates after a strong recent rebound. Is the market rightly cautious about a loss making biotech, or is sentiment lagging behind the progress in the pipeline and earnings profile? ## Price to book valuation for Biohaven, is the premium justified? On a preferred multiple basis, Biohaven looks very expensive. The stock trades on a P/B ratio of 171.2x, compared with 2.5x for the wider US biotech industry and 5.3x for its peer group, even though it remains loss making. The P/B ratio compares a company’s market value with the book value of its net assets on the balance sheet. For profitable biopharma companies with meaningful revenue, a higher P/B can reflect expectations for future returns on research, strong product franchises or valuable intangible assets that are not fully captured in book value. For Biohaven, the gap is extreme. A P/B multiple that is dozens of times higher than both the industry and peer averages suggests the market is placing a very high value on the company’s pipeline and future potential relative to its current net assets. With minimal reported revenue, ongoing losses and a less than one year cash runway flagged in the data, investors are effectively paying a substantial premium today for outcomes that are not yet reflected in earnings. Compared with the US biotech industry average P/B of 2.5x and the peer average of 5.3x, Biohaven’s 171.2x ratio is very high. The current multiple implies far stronger expectations than the typical company in the group, even before considering the separate view from the SWS DCF model that suggests the shares are trading at a steep discount to an estimate of future cash flow value. See what the numbers say about this price — find out in our valuation breakdown. **Result: Price to book ratio of 171.2x (OVERVALUED)** However, Biohaven still carries key risks as a loss making company with no reported revenue and multiple clinical trials, where outcomes, timelines and funding needs can shift the story quickly. Find out about the key risks to this Biohaven narrative. ## Another view on Biohaven’s valuation The P/B discussion makes Biohaven look very expensive, yet the SWS DCF model points in the opposite direction. At a share price of $13.85, the stock is described as trading about 74.3% below an estimate of future cash flow value of $53.83 per share, which implies a large potential valuation gap. For investors, that contrast between a very high P/B of 171.2x and a large DCF discount raises a simple question: Is the market overpaying for thin current assets, or underestimating what Biohaven’s pipeline could one day earn? Look into how the SWS DCF model arrives at its fair value. BHVN Discounted Cash Flow as at Aug 2026 Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Biohaven for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. ## Next Steps With sentiment on Biohaven split between concern over risks and optimism about future rewards, now is a good time to review the details yourself and decide where you stand. To weigh both sides in one place, start with our breakdown of 2 key rewards and 5 important warning signs ## Looking for more investment ideas beyond Biohaven? If Biohaven has sharpened your focus on stock selection, do not stop here. Give yourself more choices and widen your opportunity set with a few focused screens. - Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations through our 48 high quality undervalued stocks. - Strengthen your income stream by reviewing companies with higher yields in our list of 12 dividend fortresses. - Prioritise resilience by checking companies that show healthier balance sheets and solid fundamentals using our solid balance sheet and fundamentals stocks screener (50 results). *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### Valuation is complex, but we're here to simplify it. Discover if Biohaven might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [BHVN.US](https://longbridge.com/en/quote/BHVN.US.md) ## Related News & Research - [Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP](https://longbridge.com/en/news/296018014.md) - [Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials](https://longbridge.com/en/news/290657108.md) - [Is Wall Street Bullish or Bearish on Biogen Stock?](https://longbridge.com/en/news/296491913.md) - [Great Lakes Advisors LLC Takes Position in Biogen Inc. $BIIB](https://longbridge.com/en/news/296676602.md) - [Plato Investment Management Ltd Invests $1.49 Million in Biogen Inc. $BIIB](https://longbridge.com/en/news/296206286.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**